Abstract Three patients diagnosed with severe COVID‐19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and received tocilizumab when the disease progressed to acute respiratory distress syndrome, and died. Tocilizumab could be used in patients with severe COVID‐19 pneumonia who did not show response to a combination of antiviral therapy. However, the use of a combination antiviral therapy should be further confirmed in clinical trials.
All Keywords
【저자키워드】 COVID‐19, acute respiratory distress syndrome, Tocilizumab, Pneumonia, 【초록키워드】 Treatment, antiviral therapy, Hydroxychloroquine, Ritonavir, Favipiravir, clinical trials, COVID‐19, Patient, acute respiratory distress, Combination, syndrome, died, diagnosed, the disease, Two patient, survived, progressed, 【제목키워드】 Hydroxychloroquine, Ritonavir, COVID‐19, case sery,
【저자키워드】 COVID‐19, acute respiratory distress syndrome, Tocilizumab, Pneumonia, 【초록키워드】 Treatment, antiviral therapy, Hydroxychloroquine, Ritonavir, Favipiravir, clinical trials, COVID‐19, Patient, acute respiratory distress, Combination, syndrome, died, diagnosed, the disease, Two patient, survived, progressed, 【제목키워드】 Hydroxychloroquine, Ritonavir, COVID‐19, case sery,